886979-23-3

Upstream product

• 143-33-9 sodium cyanide 
• 773837-37-9 sodium cyanide 
• 886976-80-3 methyl 5-[4-(ethylsulfonyl)phenoxy]-2-(pyridin-2-yl)-1H-benzimidazole-6-carboxylate 
• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 

Downstream Products

• 886979-27-7 (6-[4-(ethylsulfonyl)phenoxy]-2-(pyridin-2-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-benzimidazol-5-yl)acetic acid 
• 886982-98-5 (5-[4-(ethylsulfonyl)phenoxy]-2-(pyridin-2-yl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-benzimidazol-6-yl)acetic acid 
• 886979-21-1 (5-((4-ethylsulfonyl)phenoxy)-2-(2-pyridinyl)-1H-benzimidazol-6-yl)acetonitrile 
• 886979-51-7 5-[4-(ethylsulfonyl)phenoxy]-2-(pyridin-2-yl)-6-(2H-tetrazol-5-ylmethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-benzimidazole 
• 886979-52-8 6-[4-(ethylsulfonyl)phenoxy]-2-(pyridin-2-yl)-5-(2H-tetrazol-5-ylmethyl)-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-benzimidazole 

Relevant academic research and scientific papers

The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators

The optimization of a series of benzimidazole glucokinase activators is described. We identified a novel and potent achiral benzimidazole derivative as an allosteric GK activator. This activator was designed and synthesized via removal of the chiral center of the lead compound, 6-(N-acylpyrrolidin-2-yl)benzimidazole. The activator exhibited good PK profiles in rats and dogs, and significant hypoglycemic efficacy at 1 mg/kg po dosing in a rat OGTT model. The binding site and binding mode of the benzimidazole class of GKA with GK protein was confirmed by X-ray crystallographic analysis.

ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES

A glucokinase activator is provided; and a treatment and/or a preventive for diabetes, or a treatment and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a treatment and/or a preventive for obesity are provided. The invention relates to a compound of a formula (I): [wherein R1 and R2 represent a hydrogen, etc.; R3 represents a hydrogen atom, a halogen atom, etc.; R4 each independently represents a hydrogen atom, a lower alkyl group, etc.; Q represents a carbon atom, a nitrogen atom or a sulfur atom (the sulfur atom may be mono- or di-substituted with an oxo group); R5 and R6 each represent a hydrogen atom, a lower alkyl group, etc.; X1, X2, X3 and X4 each independently represent a carbon atom or a nitrogen atom; Z represents an oxygen atom, a sulfur atom or a nitrogen atom; Ar represents an aryl or heteroaryl group optionally mono to tri-substituted with a group selected from the substituent group β; ring A represents a 5- or 6-membered nitrogen-containing heteroaromatic group; m indicates an integer of from 1 to 6; n indicates an integer of from 0 to 3; p indicates an integer of from 0 to 2 (provided that at least two of X1 to X4 are carbon atoms); q indicates 0 or 1] or its pharmaceutically-acceptable salt, which has an effect of glucokinase activation and is useful as a treatment for diabetes.